Home > Healthcare & Medical Devices > Cancer Biological Therapy Market

Cancer Biological Therapy Market Size By Product (Monoclonal Antibodies {Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies}, Vaccines {Preventive Vaccines, Therapeutic Vaccines}, Cancer Growth Blockers {Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors}, Blood Cell Growth Factors {Lenograstim, Filgrastim}, Cytokine {Interferon, Interleukin}), By Route of Administration (Oral, Injectable), COVID-19 Impact Analysis, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI676
  • Published Date: Jan 2023
  • Report Format: PDF

Industry Statistics

Cancer Biological Therapy Market size was worth more than USD 111.5 billion in 2022 and is expected to record over 7% CAGR from 2023-2032. Rising prevalence of cancer across the globe will accelerate industry expansion.
 

Get more details on this report - Request Free Sample PDF
 

The growing disease burden and incidences of cancer worldwide will have a significant impact on the cancer biological therapy industry outlook. According to the World Health Organization (WHO), cancer accounted for more than 10 million deaths in 2020. The National Institute of Cancer has further suggested that cancer-related mortality will reach 16.4 million per year by 2040 with 29.5 million new cases annually in the U.S.
 

Moreover, the fast-paced lifestyles and the higher consumption of highly processed foods, has stirred the substantial increase in alcohol intake resulting in a high prevalence of risk factors, such as obesity and type 2 diabetes. This scenario is therefore emphasizing the need for advanced biological therapies to limit or prevent the growth and spread of tumors.
 

Side effects of anti-cancer drugs may impede product demand

The rising concerns regarding the potential side effects of anti-cancer drugs and biological therapies could restrict industry progress. Some of the common adversities associated with cancer biological therapies include fever, nausea, inflammation, chronic fatigue, disorientation, and depression, among others. While the impact of these drugs varies from patient to patient, they frequently pose a severe threat to the overall health of a patient, necessitating various treatment methods to overcome added complications, result in high hospital expenditure. Nonetheless, rapid technological advancements in cancer therapies could help provide access to safer alternatives.
 

High risk of chemotherapy-induced neutropenia to foster demand for BCGF

Get more details on this report - Request Free Sample PDF
 

Cancer biological therapy market valuation from blood cell growth factors (BCGF) is estimated to surpass USD 50 billion by 2032 due to the growing concerns associated with the side effects of cancer treatments. BCGF is increasingly administered in cancer patients to improve their immunity and combat adverse effects such as lower white blood cell count caused by therapies. It helps reduce the risk of infections and potentially boost chemotherapy output by preventing any delay in the procedure. Half of the world’s cancer patients at some point suffer from chemotherapy-induced severe neutropenia, a condition referring to very low WBCs. The growing prevalence of neutropenia as a result of radiation therapy, immunotherapy, stem cell transplant, and cancer itself will also foster the product demand.
 

Recent breakthroughs in the production of orally administered drugs to boost industry dynamics

Cancer Biological Therapy Market Share, By Route of Administration, 2022 (%)

Segment

Global market share (%), 2022

Injectable

39.4%

Oral

60.6%

Get more details on this report - Request Free Sample PDF
 

Cancer biological therapy market size from the oral segment is projected to depict over 6.5% CAGR between 2023-2032. This is attributed to the surging demand for affordable cancer treatments. Oral treatments have a high preference among patients as well as physicians over injectables as they eliminate several unfavorable side effects, such as soreness at the site of injections, and fever or chills.
 

Oral drugs are easy to administer and do not require doctor’s assistance. The presence of extensive R&D initiatives and clinical trials pertaining to FDA-approved therapeutics will complement the segment development.
 

Booming geriatric patient pool to influence Europe market trends

 

Get more details on this report - Request Free Sample PDF
 

Europe cancer biological therapy market size is slated to reach over USD 55.5 billion by 2032 driven by the rising cases of cancer and the growing geriatric population in the region. According to the European Commission’s Joint Research Center (JRC), the number of individuals diagnosed with cancer is estimated to increase by nearly 18% in 2040 led by the rising geriatric patient pool. Belgium, the Netherlands, Ireland, and Denmark are some of the major hotspots with high cancer prevalence representing lucrative demand for biological therapies. In recent years, Europe has also experienced an upsurge in cancer rates among children.
 

New product launches to foster competitive landscape

Some leading companies in the cancer biological therapy market include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Merck, AstraZeneca, GlaxoSmithKline plc, ELI Lilly and Company, Incyte, Otsuka, Pfizer, Sanofi, F. Hoffmann-La Roche, Novartis, Takeda Pharmaceuticals, Seattle Genetics, Spectrum Pharmaceuticals. These companies are focusing on product innovations to achieve competitive lead.
 

Impact of the COVID-19 pandemic on the cancer biological therapy market statistics

The COVID-19 crisis negatively influenced the cancer biological therapy market with massive disruptions in the cancer care supply chain. It resulted in a radical drop in sales of cancer drugs due to increasing focus on COVID-19 treatment. With surging hospitalization rates worldwide, several healthcare facilities ceased cancer diagnosis and screening services and delayed cancer-related procedures, negatively affecting cancer therapies. However, the post-pandemic era is expected to offer lucrative opportunities for the manufacturers of cancer biological therapies on account of recovery in non-emergency services across healthcare facilities.
 

The cancer biological therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

By Product

  • Monoclonal antibodies (MAB)
    • Naked MAB
    • Conjugated MAB
    • Bispecific MAB
  • Vaccines
    • Preventive vaccines
    • Therapeutic vaccines
  • Cancer growth blockers
    • Tyrosine kinase inhibitors (TKI)
    • Proteasome inhibitors (PI)
    • mTOR inhibitors
  • Blood cell growth factors (BCGF)
    • Lenograstim
    • Filgrastim
  • Cytokines
    • Interferons
    • Interleukins

By Route of administration

  • Oral
  • Injectable

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Poland
    • Switzerland
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
    • Indonesia
    • Vietnam
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Chile
    • Columbia
    • Peru
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Iran

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for cancer biological therapy was worth more than USD 111.5 billion in 2022 and is projected to record over 7% CAGR from 2023-2032.
Blood cell growth factors (BCGF) is estimated to surpass USD 50 billion by 2032 due to increasing use in preventing side effects of cancer treatments.
Europe cancer biological therapy market size is slated to reach over USD 55.5 billion by 2032 led by rising cases of cancer and the surging geriatric population.
AbbVie Inc., Amgen Inc., Bayer AG, Merck, AstraZeneca, Incyte, Otsuka, Pfizer, Sanofi, Novartis, Seattle Genetics are some of the key manufacturers of cancer biological therapy worldwide.

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 19
  • Tables & Figures: 545
  • Countries covered: 29
  • Pages: 250
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount